Chi-Cheng Chen1,2, Chi-Ping Huang1, Yi-Tung Tsai1, Teng-Fu Hseih3, Chih-Rong Shyr4. 1. Sex Hormone Research Center, Departments of Medical Laboratory Science and Biotechnology and Urology, Graduate Institute of Clinical Medical Science, China Medical University and Hospital, Taichung, Taiwan, R.O.C. 2. Department of Urology, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, R.O.C. 3. Department of Urology, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, R.O.C. pchdf95@gmail.com chshyr@mail.cmu.edu.tw. 4. Sex Hormone Research Center, Departments of Medical Laboratory Science and Biotechnology and Urology, Graduate Institute of Clinical Medical Science, China Medical University and Hospital, Taichung, Taiwan, R.O.C. pchdf95@gmail.com chshyr@mail.cmu.edu.tw.
Abstract
BACKGROUND/AIM: Since androgens affect urothelial bladder cancer (UBC), we examined whether 5α-reductases (5-AR) have genomic alterations in UBC and whether 5α-reductase inhibitors (5-ARI) affect UBC. MATERIALS AND METHODS: The cBioPortal was used to analyze genomic alternations of 5-ARs in UBC cancer genomic datasets. Next, we used the Taiwan National Health Insurance Research database to conduct a population-based case-control study to investigate the effect of a 5-ARI, finasteride on UBC incidence. We also performed an XTT assay to examine the direct effect of finasteride on UBC cells. RESULTS: We found that 5-AR genomic alternations were observed in 29% of UBC patients and patients with alternations had shorter disease-free survival. Also, the use of finasteride with >180 cDDDs reduced the risk of UBC. Finasteride could directly inhibit UBC cell growth. CONCLUSION: Based on our findings, we concluded that 5-AR could be explored as a therapeutic target for UBC with 5-ARIs. Copyright
BACKGROUND/AIM: Since androgens affect urothelial bladder cancer (UBC), we examined whether 5α-reductases (5-AR) have genomic alterations in UBC and whether 5α-reductase inhibitors (5-ARI) affect UBC. MATERIALS AND METHODS: The cBioPortal was used to analyze genomic alternations of 5-ARs in UBCcancer genomic datasets. Next, we used the Taiwan National Health Insurance Research database to conduct a population-based case-control study to investigate the effect of a 5-ARI, finasteride on UBC incidence. We also performed an XTT assay to examine the direct effect of finasteride on UBC cells. RESULTS: We found that 5-AR genomic alternations were observed in 29% of UBCpatients and patients with alternations had shorter disease-free survival. Also, the use of finasteride with >180 cDDDs reduced the risk of UBC. Finasteride could directly inhibit UBC cell growth. CONCLUSION: Based on our findings, we concluded that 5-AR could be explored as a therapeutic target for UBC with 5-ARIs. Copyright
Authors: Shulin Wu; Sharron X Lin; Min Lu; Alexander O Subtelny; Zongwei Wang; Douglas M Dahl; Aria F Olumi; Chin-Lee Wu Journal: Int Urol Nephrol Date: 2019-06-10 Impact factor: 2.370
Authors: Denzel Zhu; William Shyr; Michelle Toker; Ethan Fram; Jinrong Cheng; Evan Z Kovac; Ilir Agalliu; Ahmed Aboumohamed; Kara L Watts Journal: World J Urol Date: 2021-11-30 Impact factor: 4.226